Core--Pathology/Genotyping

核心--病理学/基因分型

• 批准号: 7102939
• 负责人: SCOTT M LIPPMAN
• 金额: $ 42.26万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7102939
• 关键词: biomedical facility; genetic screening; genotype; human genetic material tag; human tissue; neoplasm /cancer diagnosis; nucleic acid amplification techniques; nucleic acid quantitation /detection; pathology; prostate neoplasms; sample collection; tissue /cell preparation; tissue resource /registry

DESCRIPTION (provided by applicant): The Southwest Oncology Group-led Prostate Cancer Prevention Trial (PCPT) was the first large-scale chemoprevention trial for prostate cancer (PCa). This trial, which enrolled >18,800 men, tested the ability of the 5-alpha-reductase inhibitor finasteride to reduce the period-prevalence of biopsy-proven PCa over a period of 7 years. A byproduct of the PCPT was the establishment of large specimen banks of biopsy tissue, prostatectomy specimens, serum, plasma, and white blood cells obtained from the participants at the end of the study and at various interim time points during the study. The overall aim of this revised application for Core C is to establish a Pathology and Genotyping Core in support of the molecular "Biology of the PCPT" Program Project. This core will provide expertise and resources in the following areas: 1) Archival Repository Management and Distribution of the various specimen banks established from the PCPT; 2) Histopathology, including diagnostic interpretation, microtomy, microscopy, laser-capture microdissection (LCM), immunohistochemistry (IHC), and computer-assisted image analysis; and 3) Genotyping and hormone analysis, overseeing the isolation of DNA, genotyping of samples and hormone analysis to be carried out by specialized central facilities. This revised proposal addresses all of the comments from the review of the original proposal and adds new preliminary data regarding reliability and quantification of IHC, quantification of DNA extracted from serum, and extraction and amplification of DNA from paraffin-embedded tissue sections using LCM. Genotyping has also been streamlined to ensure sufficient DNA for the proposed studies and for future PCPT biology studies. Our intent is to provide the highest quality samples and pathological services to meet the needs of the research teams in the Program Project. It is our underlying hypothesis that the quality, reliability and applicability of translational research in PCa can only be guaranteed through the use of high-quality biological specimens that are handled, processed and interpreted in a uniform manner and that can be linked to clinical information and outcome.

描述(申请人提供)：西南肿瘤组织主导的前列腺癌 预防试验(PCPT)是第一个大规模的前列腺癌(PCA)化学预防试验。这项试验招募了18,800名男性，测试了5-α-还原酶抑制剂非那雄胺在7年的时间里降低活体组织检查证实的前列腺癌发病率的能力。PCPT的一个副产品是建立了大量的活检组织、前列腺切除标本、血清、血浆和白细胞的样本库，这些样本库是在研究结束时和研究期间的不同过渡时间从参与者那里获得的。这次修订的核心C申请的总体目标是建立一个病理学和基因分型核心，以支持分子“PCPT生物学”计划项目。该中心将在以下领域提供专门知识和资源：1)从PCPT建立的各种标本库的档案库管理和分配；2)组织病理学，包括诊断解释、显微切割、显微镜、激光捕获显微解剖(LCM)、免疫组织化学(IHC)和计算机辅助图像分析；以及3)基因分型和激素分析，监督DNA的分离、样本的基因分型和由专门的中央设施进行的激素分析。这份修订后的提案处理了对原始提案的所有审查意见，并增加了新的初步数据，涉及IHC的可靠性和量化、从血清中提取的DNA的量化以及使用激光共聚焦显微镜从石蜡包埋的组织切片中提取和扩增DNA。基因分型也得到了简化，以确保为拟议的研究和未来的PCPT生物学研究提供足够的DNA。我们的目的是提供最高质量的标本和病理服务，以满足项目研究团队的需求。我们的基本假设是，质量、可靠性和 只有通过使用高质量的生物标本才能保证转化研究在PCA中的适用性，这些标本以统一的方式处理、处理和解释，并可以与临床信息和结果联系起来。